The antibiotic resistance crisis is a global issue that poses a significant threat to public health and the economy. The rapid emergence of resistant bacteria, driven by overuse and misuse of antibiotics, has led to a lack of new drug development due to economic and regulatory challenges. The Centers for Disease Control and Prevention (CDC) has classified several bacteria as urgent, serious, or concerning threats, which have already placed substantial clinical and financial burdens on healthcare systems and patients. The overuse of antibiotics, inappropriate prescribing practices, extensive agricultural use, and the limited availability of new antibiotics are key factors contributing to the crisis. Antibiotic-resistant infections, such as methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci (VRE), and multidrug-resistant gram-negative pathogens, pose significant challenges in healthcare settings and the community. These infections are associated with high mortality rates and increased healthcare costs. The economic burden of antibiotic-resistant infections is estimated to be高达数十亿美元每年。Coordinated efforts to implement new policies, renew research, and manage the crisis are迫切需要。The antibiotic resistance crisis is a global issue that poses a significant threat to public health and the economy. The rapid emergence of resistant bacteria, driven by overuse and misuse of antibiotics, has led to a lack of new drug development due to economic and regulatory challenges. The Centers for Disease Control and Prevention (CDC) has classified several bacteria as urgent, serious, or concerning threats, which have already placed substantial clinical and financial burdens on healthcare systems and patients. The overuse of antibiotics, inappropriate prescribing practices, extensive agricultural use, and the limited availability of new antibiotics are key factors contributing to the crisis. Antibiotic-resistant infections, such as methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci (VRE), and multidrug-resistant gram-negative pathogens, pose significant challenges in healthcare settings and the community. These infections are associated with high mortality rates and increased healthcare costs. The economic burden of antibiotic-resistant infections is estimated to be高达数十亿美元每年。Coordinated efforts to implement new policies, renew research, and manage the crisis are迫切需要。